Stryker Corp. yesterday announced that it completed its acquisition of Irvine-based medical device maker Inari Medical Inc. for $4.9 billion.
The acquisition closed less than two months after the deal was first announced on Jan. 6.
Inari, known for its portfolio of devices to remove large blood clots from veins, will now operate as a wholly owned subsidiary of Stryker.
“The acquisition of Inari Medical marks a significant milestone in expanding our interventional endovascular portfolio,” Stryker CEO Kevin Lobo said in a statement.
Stryker officials previously said Inari’s products, including the FlowTriever and ClotTriever systems, will be “highly complementary” to Stryker’s neurovascular business.
Shares of Inari stopped trading yesterday prior to the market opening yesterday and has been delisted from the Nasdaq.
